Market Overview

GW Pharmaceuticals Shares Jump Following Price Target Raise

Share:
Related GWPH
Why Industrial Hemp Could Prove A Larger Economic Driver Than Marijuana
5 Tips To Start A Successful (And Legal) Marijuana Grow Operation, According To Serge Chistov

In a note released Monday morning, Piper Jaffray made a big raise to the price target of GW Pharmaceuticals (NASDAQ: GWPH) from $97 to $147, citing the potential of GW's Epidiolex to treat epilepsy.

The analysts at Piper Jaffray say that the unique safety/CNS profile make the drug an attractive way to treat epilepsy.

Additionally, the analysts noted that they do not believe INSYS Therapeutics will be able to compete on price.

Following the note, shares of GW Pharmaceuticals are up over six percent in the pre-market.

Latest Ratings for GWPH

DateFirmActionFromTo
Aug 2017Maxim GroupDowngradesBuyHold
Oct 2016Leerink SwannAssumesOutperform
Sep 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color News Price Target Analyst Ratings

 

Related Articles (GWPH)

View Comments and Join the Discussion!